Literature DB >> 22901741

Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ.

Nicholas Ah Mew1, Lauren Krivitzky, Robert McCarter, Mark Batshaw, Mendel Tuchman.   

Abstract

OBJECTIVE: To compare the clinical course and outcome of patients diagnosed with one of 4 neonatal-onset urea cycle disorders (UCDs): deficiency of carbamyl phosphate synthase 1 (CPSD), ornithine transcarbamylase (OTCD), argininosuccinate synthase (ASD), or argininosuccinate lyase (ALD). STUDY
DESIGN: Clinical, biochemical, and neuropsychological data from 103 subjects with neonatal-onset UCDs were derived from the Longitudinal Study of Urea Cycle Disorders, an observational protocol of the Urea Cycle Disorders Consortium, one of the Rare Disease Clinical Research Networks.
RESULTS: Some 88% of the subjects presented clinically by age 7 days. Peak ammonia level was 963 μM in patients with proximal UCDs (CPSD or OTCD), compared with 589 μM in ASD and 573 μM in ALD. Roughly 25% of subjects with CPSD or OTCD, 18% of those with ASD, and 67% of those with ALD had a "honeymoon period," defined as the time interval from discharge from initial admission to subsequent admission for hyperammonemia, greater than 1 year. The proportion of patients with a poor outcome (IQ/Developmental Quotient <70) was greatest in ALD (68%), followed by ASD (54%) and CPSD/OTCD (47%). This trend was not significant, but was observed in both patients aged <4 years and those aged ≥ 4 years. Poor cognitive outcome was not correlated with peak ammonia level or duration of initial admission.
CONCLUSION: Neurocognitive outcomes do not differ between patients with proximal UCDs and those with distal UCDs. Factors other than hyperammonemia may contribute to poor neurocognitive outcome in the distal UCDs.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22901741      PMCID: PMC4440324          DOI: 10.1016/j.jpeds.2012.06.065

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

1.  Prospective treatment of urea cycle disorders.

Authors:  N E Maestri; E R Hauser; D Bartholomew; S W Brusilow
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

2.  Argininosuccinic aciduria.

Authors:  S D Cederbaum; K N Shaw; M Valente; M E Cotton
Journal:  Am J Ment Defic       Date:  1973-01

3.  Molecular defects in human carbamoy phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations.

Authors:  Johannes Häberle; Oleg A Shchelochkov; Jing Wang; Panagiotis Katsonis; Lynn Hall; Sara Reiss; Angela Eeds; Alecia Willis; Meeta Yadav; Samantha Summar; Olivier Lichtarge; Vicente Rubio; Lee-Jun Wong; Marshall Summar
Journal:  Hum Mutat       Date:  2011-05-05       Impact factor: 4.878

4.  Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene.

Authors:  Eva Trevisson; Leonardo Salviati; Maria Cristina Baldoin; Irene Toldo; Alberto Casarin; Sabrina Sacconi; Luca Cesaro; Giuseppe Basso; Alberto B Burlina
Journal:  Hum Mutat       Date:  2007-07       Impact factor: 4.878

5.  Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype.

Authors:  B A McCullough; M Yudkoff; M L Batshaw; J M Wilson; S E Raper; M Tuchman
Journal:  Am J Med Genet       Date:  2000-08-14

6.  Cross-sectional multicenter study of patients with urea cycle disorders in the United States.

Authors:  Mendel Tuchman; Brendan Lee; Uta Lichter-Konecki; Marshall L Summar; Marc Yudkoff; Stephen D Cederbaum; Douglas S Kerr; George A Diaz; Margaretta R Seashore; Hye-Seung Lee; Robert J McCarter; Jeffrey P Krischer; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2008-06-17       Impact factor: 4.797

7.  Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies.

Authors:  M Msall; M L Batshaw; R Suss; S W Brusilow; E D Mellits
Journal:  N Engl J Med       Date:  1984-06-07       Impact factor: 91.245

8.  Hyperammonemia.

Authors:  M L Batshaw
Journal:  Curr Probl Pediatr       Date:  1984-11

Review 9.  Argininosuccinate lyase deficiency.

Authors:  Sandesh C S Nagamani; Ayelet Erez; Brendan Lee
Journal:  Genet Med       Date:  2012-01-05       Impact factor: 8.822

10.  The Human Gene Mutation Database: 2008 update.

Authors:  Peter D Stenson; Matthew Mort; Edward V Ball; Katy Howells; Andrew D Phillips; Nick St Thomas; David N Cooper
Journal:  Genome Med       Date:  2009-01-22       Impact factor: 11.117

View more
  16 in total

1.  The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation.

Authors:  Stefan Kölker; Angeles Garcia-Cazorla; Angeles Garcia Cazorla; Vassili Valayannopoulos; Allan M Lund; Alberto B Burlina; Jolanta Sykut-Cegielska; Frits A Wijburg; Elisa Leão Teles; Jiri Zeman; Carlo Dionisi-Vici; Ivo Barić; Daniela Karall; Persephone Augoustides-Savvopoulou; Lise Aksglaede; Jean-Baptiste Arnoux; Paula Avram; Matthias R Baumgartner; Javier Blasco-Alonso; Brigitte Chabrol; Anupam Chakrapani; Kimberly Chapman; Elisenda Cortès I Saladelafont; Maria L Couce; Linda de Meirleir; Dries Dobbelaere; Veronika Dvorakova; Francesca Furlan; Florian Gleich; Wanda Gradowska; Stephanie Grünewald; Anil Jalan; Johannes Häberle; Gisela Haege; Robin Lachmann; Alexander Laemmle; Eveline Langereis; Pascale de Lonlay; Diego Martinelli; Shirou Matsumoto; Chris Mühlhausen; Hélène Ogier de Baulny; Carlos Ortez; Luis Peña-Quintana; Danijela Petković Ramadža; Esmeralda Rodrigues; Sabine Scholl-Bürgi; Etienne Sokal; Christian Staufner; Marshall L Summar; Nicholas Thompson; Roshni Vara; Inmaculada Vives Pinera; John H Walter; Monique Williams; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

2.  The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype.

Authors:  Stefan Kölker; Vassili Valayannopoulos; Alberto B Burlina; Jolanta Sykut-Cegielska; Frits A Wijburg; Elisa Leão Teles; Jiri Zeman; Carlo Dionisi-Vici; Ivo Barić; Daniela Karall; Jean-Baptiste Arnoux; Paula Avram; Matthias R Baumgartner; Javier Blasco-Alonso; S P Nikolas Boy; Marlene Bøgehus Rasmussen; Peter Burgard; Brigitte Chabrol; Anupam Chakrapani; Kimberly Chapman; Elisenda Cortès I Saladelafont; Maria L Couce; Linda de Meirleir; Dries Dobbelaere; Francesca Furlan; Florian Gleich; Maria Julieta González; Wanda Gradowska; Stephanie Grünewald; Tomas Honzik; Friederike Hörster; Hariklea Ioannou; Anil Jalan; Johannes Häberle; Gisela Haege; Eveline Langereis; Pascale de Lonlay; Diego Martinelli; Shirou Matsumoto; Chris Mühlhausen; Elaine Murphy; Hélène Ogier de Baulny; Carlos Ortez; Consuelo C Pedrón; Guillem Pintos-Morell; Luis Pena-Quintana; Danijela Petković Ramadža; Esmeralda Rodrigues; Sabine Scholl-Bürgi; Etienne Sokal; Marshall L Summar; Nicholas Thompson; Roshni Vara; Inmaculada Vives Pinera; John H Walter; Monique Williams; Allan M Lund; Angeles Garcia-Cazorla; Angeles Garcia Cazorla
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

3.  Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases.

Authors:  Roland Posset; Sven F Garbade; Nikolas Boy; Alberto B Burlina; Carlo Dionisi-Vici; Dries Dobbelaere; Angeles Garcia-Cazorla; Pascale de Lonlay; Elisa Leão Teles; Roshni Vara; Nicholas Ah Mew; Mark L Batshaw; Matthias R Baumgartner; Shawn E McCandless; Jennifer Seminara; Marshall Summar; Georg F Hoffmann; Stefan Kölker; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2019-01       Impact factor: 4.982

4.  The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders.

Authors:  Nina Hediger; Markus A Landolt; Carmen Diez-Fernandez; Martina Huemer; Johannes Häberle
Journal:  J Inherit Metab Dis       Date:  2018-03-08       Impact factor: 4.982

5.  Disease-causing mutations in the promoter and enhancer of the ornithine transcarbamylase gene.

Authors:  Yoon J Jang; Abigail L LaBella; Timothy P Feeney; Nancy Braverman; Mendel Tuchman; Hiroki Morizono; Nicholas Ah Mew; Ljubica Caldovic
Journal:  Hum Mutat       Date:  2018-01-16       Impact factor: 4.878

6.  Peripheral venous route for administration of ammonul infusion for treatment of acute hyperammonemia. An experience from a tertiary center in Saudi Arabia.

Authors:  Amal M Alhashem; Rihab M Salih; Aida I Al-Aqeel; Sarar Mohamed
Journal:  Saudi Med J       Date:  2020-01       Impact factor: 1.484

7.  Proteomic Profiling of Liver and Plasma in Chronic Ethanol Feeding Model of Hepatic Alcohol Dehydrogenase-Deficient Deer Mice.

Authors:  Kamlesh K Bhopale; Samir M Amer; Lata Kaphalia; Kizhake V Soman; John E Wiktorowicz; Ghulam A Shakeel Ansari; Bhupendra S Kaphalia
Journal:  Alcohol Clin Exp Res       Date:  2017-09-08       Impact factor: 3.455

8.  Assessing Psychological Functioning in Metabolic Disorders: Validation of the Adaptive Behavior Assessment System, Second Edition (ABAS-II), and the Behavior Rating Inventory of Executive Function (BRIEF) for Identification of Individuals at Risk.

Authors:  Susan E Waisbren; Jianping He; Robert McCarter
Journal:  JIMD Rep       Date:  2015-02-25

9.  Impact of Diagnosis and Therapy on Cognitive Function in Urea Cycle Disorders.

Authors:  Roland Posset; Andrea L Gropman; Sandesh C S Nagamani; Lindsay C Burrage; Jirair K Bedoyan; Derek Wong; Gerard T Berry; Matthias R Baumgartner; Marc Yudkoff; Matthias Zielonka; Georg F Hoffmann; Peter Burgard; Andreas Schulze; Shawn E McCandless; Angeles Garcia-Cazorla; Jennifer Seminara; Sven F Garbade; Stefan Kölker
Journal:  Ann Neurol       Date:  2019-05-13       Impact factor: 10.422

10.  Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports.

Authors:  Aseel Bin Sawad; Arti Pothukuchy; Mark Badeaux; Victoria Hodson; Gillian Bubb; Kristina Lindsley; Jennifer Uyei; George A Diaz
Journal:  JIMD Rep       Date:  2022-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.